

Drug Monograph

Drug/Drug **Androderm[®] (testosterone) 24 Hour Patch / Hormone**
Class: **Replacement Agent**
Prepared for: MO HealthNet
Prepared by: ACS, A Xerox Company

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Each transdermal patch of Androderm[®] contains 2mg of testosterone that is released over a 24 hour period.

Manufacturer: Watson Laboratories, Inc. Salt Lake City, UT 84108

Indications: Androderm[®] is a transdermal system indicated for hormone replacement therapy in males associated with a deficiency or absence of endogenous testosterone including primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).

Costs: \$04.89133 per 24 Hour Patch of Androderm[®]. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List and is a preferred agent.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Clinical Edit PDL

Type of PA Criteria: Increased Risk of ADE Preferred Agent
 Appropriate Indications PA Required

Prepared By: Joshua S. Moore, Pharm. D.
Date: January 24, 2012